Heart Diseases

Even two cigarettes a day raise heart failure risk by 50%, study finds

Even smoking two cigarettes a day can stiffen blood vessels, raise clotting, sharply increase the risk of heart failure and early death, new global research warns about the dangers of 'light' smoking

High-protein diet isn't always better: Here's when it turns risky

While protein is vital for muscle and metabolism, excessive intake, especially from red and processed meats, may put your kidneys, heart, and even cancer risk on the line, experts caution.

Are your daily habits secretly harming your heart? Here's what to know

Cardiologist Dr Dmitry Yaranov warns that habits like poor sleep, stress, and pollution can silently damage heart health-even in those who appear fit and healthy, leading to early heart failure

What breathing air at AQI 50 feels like for your lungs and body, explained

AQI 50, a figure Delhiites can only dream of, still isn't pure air. Doctor explains how even at this level, your body works to counter invisible pollutants

99% of heart patients missed these silent warning signs, finds study

A new study reveals that nearly everyone who suffers a heart attack or stroke had warning signs long before, but most never noticed them

Doctors debunk 14 dangerous myths about heart disease and fitness

Experts explain why red wine, thin bodies, exercise and fish oil are not foolproof heart protectors and how lifestyle still matters most at every age

Bristol Myers Squibb launches heart medication Kopozgo in Indian market

Bristol Myers Squibb (BMS) on Wednesday announced the launch of Kopozgo (Mavacamten), an oral, selective cardiac myosin inhibitor, in India. Kopozgo is the first and only oral, selective cardiac myosin inhibitor approved in India for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), BMS said in a statement. Mavacamten was approved by the Central Drugs Standard Control Organisation (CDSCO), with an import license issued on March 6, 2025. "Kopozgo is now available to patients in India. The approval of Kopozgo in India is based on positive efficacy and safety results from two Phase III clinical trials, EXPLORER-HCM and VALOR-HCM," the statement said. Sanjay Sharma, General Manager and Managing Director, BMS India, mentioned, "This breakthrough brings hope to individuals and families facing this condition, giving clinicians a novel therapy to address the unmet need in treatment. Bristol Myers Squibb is committed to advancing cardiovascular care fo

The silent threat of irregular heartbeats: Doctors explain arrhythmia

Stress, caffeine, and long work hours can make your heart race, but doctors explain when it crosses the line into arrhythmia and how it may trigger sudden cardiac arrest

Cocoa extract may slow ageing by cutting deadly inflammation, study finds

Daily cocoa extract supplements lowered inflammation markers and cut cardiovascular deaths by 27 per cent in a large trial, raising hopes for its role in healthy ageing

World Heart Day 2025: Heart attacks no longer just an old age problem

Once seen as a disease of the elderly, heart attacks are now striking 20- and 30-year-olds, making World Heart Day 2025 a wake-up call for urgent action

Heart failure, devices and transplants: Benefits and possibilities

Over the past decade, India's cardiovascular device market has grown into a significant health-tech segment with an estimated value of $1.55 bn and projected to reach $2.34 bn by 2030

One-third of Indian children age 5-9 have high triglycerides: Report

Over a third of India's children aged 5-9 could be having high triglycerides, with Jammu and Kashmir, West Bengal and northeastern states showing highest prevalence, according to a government report. Over 67 per cent of children in West Bengal, 64 per cent in Sikkim, 55 per cent in Nagaland, 57 per cent in Assam and 50 per cent in Jammu Kashmir were estimated to have high levels of triglycerides -- a type of blood fat that is known to increase risk of heart disease in later life. Kerala and Maharashtra were among the states showing lowest prevalence at 16.6 per cent and 19.1 per cent, respectively. 'Children in India 2025' -- the fourth edition since its start in 2008 -- was released by the Ministry of Statistics and Programme Implementation during the 29th Conference of Central and State Statistical Organisations (CoCSSO) on September 25 in Chandigarh. The report "provides a comprehensive and detailed analysis of the well-being of children in the country," the ministry said in a .

Small steps, big impact: WHO's 'Best Buys' to fight deadly NCDs worldwide

A new WHO report urges governments around the world to adopt low-cost, high-impact steps to curb heart disease, cancer, diabetes and more, warning that delay will cost lives and strain economies

Younger women face overlooked heart attack risks, Mayo Clinic warns

Researchers in the US warn that many women under 65 have heart attacks linked to artery tears or stressors, not plaque build-up, underscoring the need for better diagnosis

India's chronic disease surge hits women hardest, defying global trend

A new Lancet report highlights that India is among the few nations of the world where mortality due to non-communicable diseases increased over the past decade, bucking global improvements

Nocturia: Understanding night-time urination, causes and its solutions

Frequent urination at night is common but not always harmless. Doctors highlight the risks, underlying causes, and practical steps you can take to improve sleep and protect your health

Watch your heart! Cardiovascular disease continues to be India's top killer

Heart disease is the leading cause of death across India, followed by respiratory infections and cancers, according to the Causes of Death: 2021-2023 report

Caplin Point's unit gets USFDA nod for generic milrinone lactate injection

Pharma firm Caplin Point Laboratories Ltd on Wednesday said its arm Caplin Steriles Ltd has received final approval from the US health regulator for its generic milrinone lactate in 5 per cent dextrose injection indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. The approval granted by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) milrinone lactate in 5 per cent Dextrose Injection of strengths 20 mg/100 mL and 40 mg/200 mL in single-dose infusion bags, Caplin Point Laboratories said in a regulatory filing. The approved injection is a generic therapeutic equivalent version of the reference listed drug PRIMACOR in dextrose 5 per cent, by Sanofi Aventis US LLC, it added. Milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure, the company said. Citing IQVIA (IMS Health) data, the company said milrinone lactate in 5 per cent ...

Why it's harder to burn fat with age, and how scientists plan to fix it

Ageing slows our body's natural calorie burners, but a new study shows how reactivating beige fat could help tackle weight gain, diabetes, and heart disease

AI stethoscope trial shows promise for early heart disease detection

Large UK trial shows the AI-enabled stethoscope can detect heart failure, atrial fibrillation and valve disease in advance, but experts caution it still needs better integration into medical practices